Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses

被引：0
|
作者：
Metayer, L. [1 ]
Annereau, M. [2 ]
Abbas, R. [3 ]
Hinterlang, M. [2 ]
Schleiermacher, G. [4 ]
Defachelles, A. S. [5 ]
Pasqualini, C. [1 ]
Berlanga, P. [1 ]
Vassal, G. [6 ]
Valteau-Couanet, D. [1 ]
机构：
[1] Gustave Roussy, Dept Childhood & Adolescent Oncol, Villejuif, France
[2] Gustave Roussy, Dept Pharm, Villejuif, France
[3] Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France
[4] Inst Curie, Dept Paediat Oncol, Paris, France
[5] Ctr Oscar Lambret, Dept Paediat Oncol, Lille, France
[6] Gustave Roussy, Dept Clin Res, Villejuif, France
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP052 SIOP
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [41] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
  • [42] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    A J Jakubowiak
    D S Siegel
    T Martin
    M Wang
    R Vij
    S Lonial
    S Trudel
    V Kukreti
    N Bahlis
    M Alsina
    A Chanan-Khan
    F Buadi
    F J Reu
    G Somlo
    J Zonder
    K Song
    A K Stewart
    E Stadtmauer
    B L Harrison
    A F Wong
    R Z Orlowski
    S Jagannath
    Leukemia, 2013, 27 : 2351 - 2356
  • [43] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [44] Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data
    Wieczorek, Aleksandra
    Zebrowska, Urszula
    Ussowicz, Marek
    Sokol, Agnieszka
    Stypinska, Marzena
    Dembowska-Baginska, Bozenna
    Pawinska-Wasikowska, Katarzyna
    Balwierz, Walentyna
    Barutello, Giuseppina
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (16)
  • [45] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    Jakubowiak, A. J.
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B. L.
    Wong, A. F.
    Orlowski, R. Z.
    Jagannath, S.
    LEUKEMIA, 2013, 27 (12) : 2351 - 2356
  • [46] Minimal Residual Disease in Bone Marrow of Patients with High Risk Neuroblastoma in 31 Patients from a Single Institution in Argentina
    Cimolai, M.
    Medina, A.
    Mitchell, R.
    Rubio, P.
    Rossi, J.
    Zubizarreta, P.
    Cacciavillano, W.
    Alonso, C.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S225 - S226
  • [47] A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
    Ines De La Fuente, Macarena
    Colman, Howard
    Rosenthal, Mark
    Andrew Van Tine, Brian
    Levaci, Danijela
    Walbert, Tobias
    Gan, Hui Kong
    Vieito, Maria
    Milhem, Mohammed M.
    Lipford, Kate
    Forsyth, Sanjeev
    Mireille Guichard, Sylvie
    Mikhailov, Yelena
    Sedkov, Alexander
    Thomson, Blythe
    Francis Kelly, Patrick
    Monga, Varun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Papadopoulos, Kyriakos P.
    Siegel, David S.
    Vesole, David H.
    Lee, Peter
    Rosen, Steven T.
    Zojwalla, Naseem
    Holahan, Joseph R.
    Lee, Susan
    Wang, Zhengping
    Badros, Ashraf
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) : 732 - 739
  • [49] Prognostic value of PET/CT in patients with lymphoma treated with autologous stem cell transplantation for relapsed/refractory or high risk disease
    Stefani, Piero M.
    Salvadori, Ugo
    Gottardi, Michele
    Bissoli, Sergio
    Chierichetti, Franca
    Gherlinzoni, Filippo
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (01): : 62 - 67
  • [50] Randomized Comparisons of Bevacizumab(B) and Irinotecan(I), Added to Temozolomide(T), In Children With Relapsed/Refractory High-Risk Neuroblastoma(RR-HRNB); Survival Results of the ITCC-SIOPEN Beacon-Neuroblastoma Phase 2 Trial
    Wheatley, K.
    Holt, G.
    Owens, C.
    Valteau-Couanet, D.
    Gambart, M.
    Castel, V.
    Van Eijkelenburg, N.
    Castellano, A.
    Nysom, K.
    Gerber, N.
    Laureys, G.
    Ladenstein, R.
    Makin, G.
    Vaidya, S.
    Thebaud, E.
    Kearns, P.
    Pearson, A.
    Moreno, L.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S31 - S31
12345